Abstract
We assessed peripheral and liver CXCL10 levels in 15 patients treated with telaprevir/pegylated interferon/ribavirin. Induction of peripheral CXCL10 messenger RNA (mRNA) peaked (mean fold-induction [±SD], 3.1 ± 1.9) between treatment hour 6 and day 2, while induction of intrahepatic CXCL10 mRNA peaked (mean fold-induction [±SD], 1.3 ± 0.54) at hour 10 or day 4. Peripheral CXCL10 levels were higher at treatment hour 10 (P = .032) and day 2 (P = .009) in patients with undetectable virus 2 weeks after treatment initiation. Treatment hour 10 (P = .023) and peak (P = .034) intrahepatic CXCL10 levels were also higher in these patients. CXCL10 did not distinguish treatment responders from nonresponders. In conclusion, CXCL10 identified very rapid virological response in patients treated with a direct-acting antiviral.
Clinical trials registration:
NCT00892697.
Keywords:
CXCL10; HCV; chemokines; liver inflammation.
© The Author 2014. Published by Oxford University Press on behalf of the Infectious Diseases Society of America. All rights reserved. For Permissions, please e-mail: journals.permissions@oup.com.
Publication types
-
Clinical Trial
-
Research Support, N.I.H., Extramural
-
Research Support, Non-U.S. Gov't
MeSH terms
-
Adolescent
-
Adult
-
Aged
-
Antiviral Agents / pharmacology
-
Antiviral Agents / therapeutic use*
-
Chemokine CXCL10 / analysis
-
Chemokine CXCL10 / blood*
-
Chemokine CXCL10 / genetics
-
Chemokine CXCL10 / metabolism*
-
Female
-
Hepacivirus / drug effects
-
Hepatitis C, Chronic / drug therapy
-
Hepatitis C, Chronic / epidemiology
-
Hepatitis C, Chronic / immunology*
-
Humans
-
Interferon-alpha / pharmacology
-
Interferon-alpha / therapeutic use*
-
Liver / chemistry
-
Liver / immunology
-
Liver / metabolism
-
Male
-
Middle Aged
-
Oligopeptides / pharmacology
-
Oligopeptides / therapeutic use*
-
Polyethylene Glycols / pharmacology
-
Polyethylene Glycols / therapeutic use*
-
Recombinant Proteins / pharmacology
-
Recombinant Proteins / therapeutic use
-
Ribavirin / pharmacology
-
Ribavirin / therapeutic use*
-
Viral Load / drug effects
-
Young Adult
Substances
-
Antiviral Agents
-
CXCL10 protein, human
-
Chemokine CXCL10
-
Interferon-alpha
-
Oligopeptides
-
Recombinant Proteins
-
Polyethylene Glycols
-
Ribavirin
-
telaprevir
-
peginterferon alfa-2a
Associated data
-
ClinicalTrials.gov/NCT00892697